¶íÂÞ˹¹ó±ö»á¼¯ÍÅ

English ¶íÂÞ˹¹ó±ö»á¼¯Íż¯ÍÅÆóÒµÓÊÏä
icon_searchclose

MEBOÔÚ¼¤¹âìî°ß´´ÃæÖеÄÒ½ÖÎ×÷ÓÃ

2012Äê-07ÔÂ-23ÈÕ ÆðÔ´£º

½ð²ýÊÐÁøÌúÖÐÐÄÒ½ÔºÕûÐÎ±í¿Æ  Ö쵤±ë  ÇØºèÖ¾  Áú  ê¿

¡¾ÌáÒª¡¿Ö÷ÕÅ  ¹Û²ì¶íÂÞ˹¹ó±ö»á¼¯ÍÅʪÈóÉÕÉ˸ࣨMEBO£©¶Ô¼¤¹âìî°ßÊõºó´´ÃæÓúºÏµÄ³ÉЧ¡£²½Öè  ½«120Àý¼¤¹âìî°ßÊõºóµÄ»¼Õߣ¬Ëæ»ú·ÖΪҽÖÎ×éºÍ¶ÔÕÕ×飬¸÷60Àý£¬Ò½ÖÎ×éÊõºóÔÚ´´ÃæÍ¿Ä¨MEBO£¬Ã¿Ìì4´Î~6´Î£¬Î¬³Ö´´Ãæ³ÊʪÈó״ֱ̬ÖÁ´´ÃæÓúºÏ£»¶ÔÕÕ×é´´ÃæÍ¿ÒÔºìÃ¹ËØÈí¸à£¬Ã¿Ìì4´Î~6´Î£¬Ö±ÖÁ´´ÃæÓúºÏ¡£¹Û²ì2×éÔÚÊõºóµÄֹʹ³ÉЧ¡¢´´ÃæÓúÓ¦¹¦·ò¡¢É«ËØÕò¶¨¼°ÆäÏûÍ˵ȷ½ÃæµÄÁÆÐ§¡£Á˾֠ Ò½ÖÎ×éÊõºóÌÛÍ´ºÍ´´ÃæÓúÓ¦¹¦·òÓë¶ÔÕÕ×é±ÈÁ¦ÓÐÏÔÖø²î¾à£¨P£¼0.01£©£»Êõºó´´ÃæÉ«ËØÕò¶¨Çé¿öÁ½×éÏà±È²î¾àÎÞͳ¼ÆÑ§Òâ˼£¬µ«ÔÚ´´ÃæÉ«ËØÕò¶¨µÄÏûÍ˹¦·òÉÏ£¬Ò½ÖÎ×é±È¶ÔÕÕ×éÏÔÖøËõ¶Ì£¬²î¾àÏÔÖø£¨P£¼0.01£©¡£½áÂÛ  MEBO¶Ô¼¤¹âìî°ßÊõºó´´ÃæÓµÓм±¾çֹʹ¡¢Ëõ¶Ì´´ÃæÓúÓ¦¹¦·ò¡¢ÍƽøÉ«ËØÕò¶¨ÏûÍ˵Ä×÷Óã¬ÊÇ´¦Öü¤¹âÊõºó´´ÃæµÄÃÎÏë²½Öè¡£
¡¾¹Ø¼ü´Ê¡¿¶íÂÞ˹¹ó±ö»á¼¯ÍÅʪÈóÉÕÉ˸ࣻ¼¤¹â£»ìî°ß£»ºìÃ¹ËØÈí¸à
¡¾Abstract¡¿Objective  To observe the therapeutic effect of MEBO Wound Ointment £¨MEBO£©in the treatment of surgical sites after spot area laser therapy. Method The 120 patients after spot area laser therapy were randomly and evenly divided into treatment group and control group. In treatment group, MEBO Wound Ointment was administered after surgery for 4-6 times a day, keeping the surgical sites moist until wound healing; In control group, the surgical sites were applied with erythromycin ointment for 4-6 times a day until healing. And then, the indicators of therapeutic effects, such as the postoperative pain relief, wound healing days, pigment deposition and fading were observed in two groups. Results Compared to control group, the postoperative pain relief and wound healing days in treatment group had significant differences(P£¼0.01); pigment deposition in two groups showed no statistical difference, but the fading time of pigment in treatment group was significantly shorter than that in control group (P£¼0.01). Conclusion MEBO Wound Ointment in the treatment of surgical wounds after spot area laser therapy is effective on rapid relief of pain, shortening healing time and promoting pigment fading, thus is an ideal therapeutic approach in the treatment of surgical wounds after laser therapy.
¡¾Key words¡¿MEBO Wound Ointment; Laser; Spot area surgery; Erythromycin ointment
½üÄêÀ´£¬ÀûÓü¤¹âìî°ßµÄÒ½Öβ½ÖèÒѾ­¿í·ºÀûÓã¬ÓÈÆäÒÔYAG¼¤¹âìî°ß²½ÖèΪ´ú±í£¬³ÉЧȷÇС£Ò½ÖεÀÀíÊÇÀûÓü¤¹âµÄÑ¡ÔñÐÔ¹âÈÈ×÷ÓÃÒ½ÖÎÉ«ËØ²¡±ä£¬ÀûÒæÊÇÄÜÔ¤·À´ó²¿·Ô줷ô×éÖ¯µÄΣÏÕ´Ó¶ø²»Ò׳öÏÖñ£ºÛ¡£µ«¼¤¹âÒ½Öκó´´ÃæµÄ´¦ÖÃÒ²¼«¶È¹Ø¼ü£¬ÈôÊÇ´´ÃæÓÃÒ©²»µ±£¬²»Ö»µ¢¸éÓúÓ¦¹¦·ò£¬ÉõÖÁ»áÔì³ÉϰȾ£¬µ¼ÖÂñ£ºÛÐγÉ¡£Ä¿Ç°¼¤¹âÒ½ÖκóµÄ´´ÃæÓÃÒ©±ÈÁ¦ÔÓÂÒ£¬ÓбíÍ¿µâ·ü¡¢¿µ¸´Ð¡¢Ë«ÑõË®µÈÒ©Ë®£¬Ò²ÓбíÍ¿ºìÃ¹ËØ¡¢½ðÃ¹ËØ¡¢ÉÕÉ˸àµÈ¸÷ÀàÒ©¸àÕß¡£ÎÒ¿ÆÓÚ1996Äê10ÔÂÖÁ1999Äê10Լ䣬¶Ô120Àý¼¤¹âìî°ßÊõºó´´ÃæµÄ´¦ÖñðÀëѡȡMEBOºÍºìÃ¹ËØÈí¸àͿĨ´´Ã棬²¢½øÐÐÁËÁÆÐ§¹Û²ìºÍ±ÈÁ¦·ÖÎö¡£ÏÖ±¨Â·ÈçÏ£º
1.×ÊÁÏÓë²½Öè
1.1.ͨ³£×ÊÁÏ
½«¼¤¹âìî°ßÒ½ÖεÄ120Àý»¼Õߣ¬Ëæ»ú·ÖΪÁ½×飺ҽÖÎ×éºÍ¶ÔÕÕ×飬¸÷60Àý¡£Ò½ÖÎ×éѡȡ¶íÂÞ˹¹ó±ö»á¼¯ÍÅʪÈóÉÕÉ˸ࣨMEBO£©Ê¹ÓÃʪÐÔÒ½Ò©¼¼ÊõÒ½ÖΣ»¶ÔÕÕ×éѡȡºìÃ¹ËØÈí¸à±íÍ¿£¬Á½×é¾ùѡȡ´´ÃæÂ¶³öÁÆ·¨Ò½ÖΡ£Ì«Ìïðë58Àý£¬°ßµã37Àý£¬¿§·È°ß25Àý£»Å®ÐÔ98Àý£¬ÄÐÐÔ22Àý£»´ºÇï14Ëê~46Ë꣬¾ùÔÈ28.5Ë꣬Éí¶Î½¡È«£¬¾ùΪÃÅÕﻼÕß¡£
1.2.²½Öè
ѡȡͨÀýµâ¾Æ¡¢¾Æ¾«Ïû¶¾´´Ã棬ÊõÇø²¿ÃÅÓÃ0.5%Àû¶à¿¨ÒòÉúÀíÑÎË®ÈÜÒº½þÈóÂé×í£¬¶øºóÓÃË«²¨³¤Âö³åµ÷Q¼¤¹â£¨³¤´º¾°»úËù³ö²úµÄYQ400-A/BI£©½øÐÐÒ½ÖΣ¬¼¤»ÝÁÙ´²²ÎÊýµÄÉ趨ƾ¾Ý²¡±äµ÷Õû£¬¼¤¹âµÄ²¨³¤¡¢ÄÜÁ¿Ãܶȡ¢¹â°ß¡¢Âö¿íºÍƵÂÊӦƾ¾Ý»¼ÕߵĴºÇï¡¢·ôÉ«¡¢²¡±ä²¿Î»¡¢²¡±äÉ«²Ê½øÐÐÉ趨£»±¾¼¤¹âÓÐ532 nmºÍ1064 nmÁ½¸ö²¨³¤¡£¼¤¹âÒ½ÖνáÊøºó£¬ÒÀÕÕÆ¤·ôԭλÔÙÉúÒ½ÁƼ¼Êõ½øÐд´Ãæ´¦Ö㺲»Ê¹Óô̼¤ÐÔÏû¶¾Òº£¬ÓÃÎÞ¾úÉúÀíÑÎˮϴ媸ɾ»¡£¶øºóÒ½ÖÎ×éѡȡ¶íÂÞ˹¹ó±ö»á¼¯ÍÅʪÈóÉÕÉ˸à±íÍ¿£¬¿ÉÓÃѹÉà°å»òÃÞÇ©½«Æä¾ùÔÈͿĨÓÚ´´Ã棬ºñ1 mm~2 mm£¬4 h~6 h»»Ò©1´Î£¬Ã¿´ÎͿҩǰ½«´´Ãæ²ÐÁôµÄÒ©ÎïºÍÉø³öÎï¶Ï¸ù¸É¾»£¬¿ÉÏÅ×ÃÎÞ¾úÉúÀíÑÎˮϴ媴´Ã棬¶øºóÍ¿¶íÂÞ˹¹ó±ö»á¼¯ÍÅʪÈóÉÕÉ˸࣬Ӧʱ¿Ìά³Ö´´Ãæ³ÊʪÈó״̬£¬Ô¤·À´´Ãæ½áð裬ֱÖÁ´´ÃæÓúºÏ¡£¶ÔÕÕ×éѡȡ1%ºìÃ¹ËØÈí¸à±íÍ¿£¨Í¿Ò©ºñ¶È¡¢»»Ò©¹¦·ò¡¢´´ÃæÏ´åªµÈºÍÒ½ÖÎ×éÒ»Ñù£©£¬Ö±ÖÁ´´ÃæÓúºÏ¡£Á½×é¾ù¹Û²ì¼Í¼´´ÃæÓúÓ¦¹¦·ò¡¢ÊõºóÌÛÍ´Çé¿ö£¬²¢Ëæ·Ã6¸öÔÂÖÁ9¸öÔ£¬¹Û²ì´´ÃæÉ«ËØÕò¶¨Çé¿ö¡£´´ÃæÓúºÏºó¸¶Íл¼Õß°ÑÎÈ·Àɹ£¬ÒÔÔ¤·ÀÉ«ËØÕò¶¨£¬Í¬Ê±·þÓÃάÉúËØc¼õÇáÉ«ËØÕò¶¨¡£
1.3.¹Û²ìÖ¸±ê
¢Ù´´ÃæÓúÓ¦¹¦·ò£»¢ÚÊõºóÌÛÍ´£»¢ÛÉ«ËØÕò¶¨¡£
1.4.ͳ¼ÆÑ§´¦ÖÃ
ÀûÓÃÍÆËã»úSPSS 11.0ͳ¼ÆÈí¼þ½øÐÐͳ¼ÆÑ§´¦Ö㬼ÆÁ¿×ÊÁϾùÒÔx(_)¡Às°µÊ¾£¬Ñ¡È¡t¼ìÑé²â¶¨ÆäÏÔÖøÐÔ£»¼ÆÊý×ÊÁÏÒÔÂʰµÊ¾£¬×é¼äµÄ±ÈÁ¦Ñ¡È¡¦Ö2¼ìÑ飬P£¼0.05Ϊ²î¾àÓÐͳ¼ÆÑ§Òâ˼¡£
2.Á˾Ö
MEBO×éµÄ´´ÃæÓúÓ¦¹¦·òÒÔ¼°´´ÃæÊõºóÌÛÍ´Çé¿öÓëºìÃ¹ËØÈí¸à×éÏà±È£¬P£¼0.01£¬ÓÐÏÔÖøÐÔ²î¾à£ºMEBO¿ÉÄÜÏÔÖø¼õÇá´´ÃæÌÛÍ´ÒÔ¼°Íƽø´´ÃæÓúºÏ£¨¼û±í1¡¢±í2£©¡£Á½×é´´ÃæÓúºÏºó³öÏÖÉ«ËØÕò¶¨µÄ²î¾àÎÞͳ¼ÆÑ§Òâ˼£¨P£¾0.05£©£¬µ«ÊÇ´ÓÉ«ËØÕò¶¨¹¦·òµÄÏûÍËÉÏ¿´£ºMEBO×éµÄ´´ÃæÉ«ËØÕò¶¨³ÖÐø¹¦·ò±ÈºìÃ¹ËØÈí¸à×éÏÔÖøËõ¶Ì£¨P£¼0.01£¬¼û±í3£©¡£

201272394342178

3.»áÉÌ
3.1.ÍÆ½ø´´ÃæÓúºÏ
MEBOÊÇÒ»ÖÖ¿ò¼ÜÈí¸à¼Á£¬º¬ÓлÆÜË¡¢»Æ°Ø¡¢·äÀ¯¡¢ÂéÓ͵ȳɷÖ£¬²»½öÄÜ¿¹Ï°È¾¡¢ìÉú¼¡¡¢»îѪ»¯ðö£¬ÎªÔ­Î»¸Éϸ°ûÔÙÉú½¨¸´´´ÔìǰÌᣬÍƽø´´ÃæµÄÓúºÏ£¬²¢ÇÒÈí¸àÖеĦÂ-¹ÈçÞ´¼¿É¸ÄÉÆ²¿ÃÅ΢ѭ»·£¬¼õÇᲿÃÅ×éÖ¯ÓÙÖÍΣÏÕ£¬Ê¹×éÖ¯×î´óÏ޶ȵصõ½¸´Ëճɳ¤£¬ÉÏÆ¤Ï¸°ûѸËÙÔöÖ³£¬´Ó¶ø´Ùʹ´´ÃæÓúºÏ[1]¡£±¾³¢ÊÔ¼¤¹âÒ½ÖκóµÄ´´ÃæÀàËÆÓÚdz¢ò¶ÈÉÕÌÌÉË´´Ã棬¶øMEBOÔÚÉÕÉË»òÌÌÉËµÈÆ¤·ôΣÏÕÖÐÒѾ­µÃµ½¼«Îª¿í·ºµÄÀûÓã¬ÇÒ³ÉЧÓÅÁ¼£¬ÊÇÒ½ÖÎÉÕÉË»òÌÌÉËµÈÆ¤·ôΣÏÕµÄÊ×Ñ¡ÓÃÒ©£¬ËùÒÔ½«MEBOʹÓÃÔÚ¼¤¹âìî°ßÊõºóµÄ´´ÃæÊÇÓÐÆ¾¾ÝµÄ¡£ÓÉÓÚMEBOʹÓÃ¿í·ºÇÒ±»²»ÐݵØÍÚ¾ò£¬Òò¶øMEBOÔÚÕûÐÎÃÀÈÝרҵҲµÃµ½ºÜºÃµÄÀûÓá£È磺CO2¼¤¹âÒ½ÖÎÆ¤·ô»òð¤Ä¤ÉϵÄðà»ò׸ÉúÎïµÄ´´Ãæ[2]£»Ë«²¨³¤Âö³åµ÷QND:YAG¼¤¹âÒ½Öλúϴü¡¢ÑÛÏß¡¢ÎÆÉí¡¢Ãæ²¿°ßµãµÈ´´Ãæ[3]£»ÒÔ¼°Ö²Æ¤ºó¹©Çø´´ÃæµÄÒ½ÖεȵÈ£¬¶¼Ö¤Ã÷MEBO¶ÔƤ·ô´´ÉËÓÐÓÅÁ¼µÄÓúºÏ×÷Óá£
3.2.ÍÆ½øÉ«ËØÕò¶¨µÄÏûÍË
ÑÇÖÞÈËÔÚÆ¤·ôÊÜËðºóÈÝÒ׳öÏÖÉ«ËØÕò¶¨£¬µ«´ó¶àÄܹ»×ÔÐÐÏûÍË£¬¹¦·ò×ݺύ´í£¬Í¨³£Îª2¸öÔÂ~6¸öÔ£¬ÉÙÊý»¼ÕßÄÑÒÔÉõÖÁÓÆ¾Ã²»ÍË£¬ÊÇÆ¤·ôÒ½ÖΣ¨Ä¥Ï÷£¬¼¤¹âµÈ£©µÄ³£¼û²¢·¢Ö¢£¬»ÆÖÖÈ˸üΪÏÔÖø¡£Æ¤·ôÔâµ½¸÷Àà´´ÉË£¨²ÁÉË¡¢ÉÕÌÌÉË¡¢Ä¥Ï÷¡¢¼¤¹âµÈ£©ÓúºÏºó£¬ÓÐ85%µÄ»¼Õß³öÏÖÉ«ËØÕò¶¨[4]£¬Ò²Óм«ÉÙÊý»¼ÕßÔÚ´´ÃæÓúºÏÈ´ÁôÏÂÉ«ËØÍÑʧ¡£É«ËØÕò¶¨µÄ»úÔìĿǰÉÐδÆëÈ«ÁËÈ»£¬µ«´Ó±¾ÁÙ´²×êÑÐÄܹ»¿´µ½£ºÁ½×éÒ½Öβ½Öè¶Ô´´ÃæÓúºÏºó³öÏÖÉ«ËØÕò¶¨µÄ²î¾àËäÎÞͳ¼ÆÑ§Òâ˼£¬µ«MEBO×éµÄ´´ÃæÉ«ËØÕò¶¨ÏûÍ˹¦·ò±ÈºìÃ¹ËØÈí¸à×éÏÔÖøËõ¶Ì¡£ÎÒÃÇ˼¿¼É«ËØÕò¶¨¿ÉÄÜÓë´´ÃæµÄÓúÓ¦¹¦·òÓйØ£¬´´ÃæÔ½ÔçÓúºÏ£¬²¢ÇÒÓúºÏÖÊÁ¿Ô½ºÃ£¬É«ËØÕò¶¨µÄÏûÍ˾ÍÔ½¿ì¡£Áí±í£¬´´ÃæÉ«ËØÕò¶¨ÏûÍËÓëMEBO³É·ÖÊÇ·ñÓйØ£¬Óдý½øÒ»²½ÇóÖ¤¡£
3.3.»º½â´´ÃæÌÛÍ´
Àû¶à¿¨Òò£¨¼ÓÉöÉÏÏÙËØ£©µÄ¾ÖÂé³ÉЧͨ³£»á³ÖÐø1 h~2 h£¬¶ÔÕÕ×éÔÚ¾ÖÂé³ÉЧ½â³ýºó»áÓÐ¶ÌÆÚÀ±Í´¸Ð´¥£¨5 min~30 min£©£¬ºìÃ¹ËØÈí¸àµÄ´Ì¼¤×÷ÓÃʱʱÒýÆðÎÞÊý»¼ÕßÒ½ÖÎÇøÆ¤·ô×ÆÍ´£¬¶øÒ½ÖÎ×é±íÍ¿¶íÂÞ˹¹ó±ö»á¼¯ÍÅʪÈóÉÕÉ˸àºó£¬³ý7ÀýÓÐ¶ÌÆÚµÄÀ±Í´¸Ð´¥±í£¬ÆäÓà¾ùÎÞÌÛÍ´¸Ð´¥¡£²¢ÇҸд¥¶ÌÆÚÌÛÍ´µÄ7Àý»¼Õߣ¬Ò²ÔÚ±íÓöíÂÞ˹¹ó±ö»á¼¯ÍÅʪÈóÉÕÉ˸àÔ¼10 minºóÌÛÍ´Òþû£¬¾­·ÖÎöºó·¢ÏÖÊÇÒòÕâ7Àý»¼ÕßÉ«°ßÃæ»ý½Ï´ó£¬¼¤¹âÒ½Öι¦·ò½Ï³¤£¬³¬¹ý2 h£¬ÒѾ­¹ýÖÕ¾ÖÂé³ÖÐø¹¦·ò£¬´´Ãæ³öÏÖÀ±Í´¸Ð´¥£¬µ«¾­¹ý±íÍ¿¶íÂÞ˹¹ó±ö»á¼¯ÍÅʪÈóÉÕÉ˸àºóÌÛÍ´»º½â£¬ÕâÊÇÓÉÓÚ¶íÂÞ˹¹ó±ö»á¼¯ÍÅʪÈóÉÕÉ˸àÓµÓÐֹʹ×÷ÓÃ[5]£¨Ô¼Ðè10 minÄÜÁ¦²ûÑïֹʹ×÷Óã©¡£MEBOֹʹµÄ»úÀí£º£¨1£©MEBOÓë´´ÃæµÄ»µËÀ±À½â×éÖ¯²úÉú»¯Ñ§·´Ó³£¬¶øÓëÓлîÁ¦µÄ×éÖ¯²»²úÉú·´Ó³£¬·´¶ø¿ÉÔÚÆäÉÏÐγɱ£»¤Ä¤£¬±£»¤Â¶³öµÄÉñ¾­Ä©ÉÒ£¬´ïµ½Ö¹Í´³ÉЧ£»£¨2£©ÀûÓÃMEBOºó¿Éʹ´´ÃæÊªÈó£¬ÇÒ¿¿½üÉúÀí»·¾³£¬Ô¤·ÀÁ˸ÉÔï½áðèµÄÊÕËõ¶øÇ£À­´´Ãæ×éÖ¯ËùÖµÄÌÛÍ´£»£¨3£©MEBOµÄ±£»¤´´ÃæºÍÒýÁ÷µÈ×÷Ó㬼õÇáÁË´´ÃæµÄÑ×Ö¢·´Ó³£¬Ê¹²¿ÃÅ×é֯ˮÖ×¼õÇᣬ¶ÔÉñ¾­Ä©ÉÔµÄѹÆÈºÍ´Ì¼¤Ï÷¼õ£¬ÌÛÍ´ÌìÈ»¼õÇá¡£
²Î¿¼Îļþ
[1]ÐìÈÙÏé.ÉÕÉËÒ½ÁƼ¼ÊõÀ¶Æ¤±¾£¨µÚ1¾í£©[M].ÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2000£º45~46.
[2]Ñî¾ü£¬»Ý½Ý£¬Ðìºì. MEBOÓëºìÃ¹ËØÑÛ¸àÒ½ÖÎCO2¼¤¹â´´ÃæµÄÁÆÐ§·ÖÎö[J]. ÖйúÉÕÉË´´ÑñÔÓÖ¾,2008,20(4):314~316.
[3]Àîǿʢ£¬Áõ²ßÀø£¬ÒóÓ£¬µÈ. MEBOÔÚ¼¤¹âÃÀÈÝÒ½ÖÎÖеÄÀûÓÃ[J]. ÖйúÉÕÉË´´ÑñÔÓÖ¾,2007,19(1):72~74.
[4]Plensdorf S,Martinez J.Common pigmentation disorders[J]. American Family Physician,2009,79(2):21~23.
[5]Íõ¹úÔ¨£¬ÕŽðÁú.MEBO½áºÏºì¹âÕÕÉäÒ½ÖÎÉÕÉË´´ÃæµÄÁÆÐ§¹Û²ì[J].ÖйúÉÕÉË´´ÑñÔÓÖ¾£¬2009£¬21£¨4£©£º270~271.

¡¾ÍøÕ¾µØÍ¼¡¿